Search PubMedSearch

Biomedical subjects

T Junghanss

Publications and source records attributed to T Junghanss.

4 recordsLinked to original sources

[Acute schistosomiasis in travellers to the tropics].

Two of three members (a 29-year-old man [case 1] and a 26-year-old woman [case 2]) of a tourist party to the tropics (Mali) developed a high fever (less than or equal to 40 degrees C), headache, cough, weight loss (less than or equal to 5 kg) and tiredness 3-4 weeks after returning to Germany. In case 1, acute schistosomiasis was tentatively diagnosed as the cause because he reported an attack of dermatitis after exposure to fresh water in an endemic schistosomiasis region and had marked eosinophilia (2118/microliters; 28%) on admission. Serological tests were positive (ELISA with adult antigen, O.D. 0.65 [normal less than 0.15]; with egg antigen O.D. 1.73 [normal less than 0.30], antibody titre in the immunofluorescence test 1:320 [normal less than 1:80]) supported the diagnosis and it was confirmed by demonstrating the parasite, Schistosoma mansoni, in stool but not urine. Findings in case 2 were similar. The third member of the group [case 3], a 58-year-old woman, was symptom-free, but tests revealed schistosomiasis. All three patients were treated with a single dose of Praziquantel (40 mg/kg). A second course of praziquantel (single dose of 40 mg/kg as well as 20 mg/kg three times daily for 3 days) became necessary in case 1, while in case 3 a further single dose of 40 mg/kg was given to ensure a parasite-free state. A follow-up scheme is suggested: clinical examination with white cell and differential counts 1, 3, 6 and 12 months after treatment; three stool and/or urine examinations 3, 6 and 12 months after treatment.

Adult

[Malaria study].

Compliance with malaria prophylaxis or reserve drugs was investigated in 477 individuals travelling to regions with endemic malaria. Correct intake of prophylactic medication was confirmed in 225 out of 285 (= 78%). Compliance was independent of type of drug (Mefloquine, Sulfadoxine-Pyrimethamine, Chloroquine). Two tourists missed to start prophylaxis one week before the onset of their travel. 14 travellers stopped prophylactic medication too early after their return, 31 tourists took too high doses of mefloquine. None of the tourists travelling to countries with a therapeutic reserve only became sick, whereas two travelling to Africa contracted malaria.

Antimalarials

[East African sleeping sickness (Trypanosoma rhodesiense infection) in 2 Swiss travelers to the tropics].

We report on two Swiss travellers who acquired African sleeping sickness (Trypanosoma rhodesiense) the same day while visiting the Akagera park in Rwanda. The first patient developed clinical signs of sleeping sickness 8 days after being bitten by a tsetse fly. Trypanosomes were demonstrated in the blood and CSF. The other patient fell ill 13 days after the bite and trypanosomes were found only in blood samples. The first patient (cerebral trypanosomiasis), was treated with melarsoprol. He developed an allergic reaction under treatment but made a good recovery 4 months later. The second patient (hemo-lymphatic trypanosomiasis) was put on suramin, which was well tolerated. He recovered after 2 months.

Adult

[Onchocerciasis in travelers to the tropics].

Two men, aged 54 and 31 years respectively, developed an itching skin rash 18 and 6 months respectively after returning from a trip to Africa, the former also recurrent conjunctivitis. Two years and 6 months, respectively, passed from the time of first symptoms until the diagnosis of onchocerciasis was made. Both patients had an eosinophilia (10.5 and 19%) and specific antibodies against Onchocerca volvulus. Microfilaria were demonstrated in the skin of the younger man. The other one had bilateral corneal infiltrates. Both patients were treated with a single dose of ivermectin, 150 micrograms/kg. Within several months, the clinical symptoms and eosinophilia disappeared and the antibody titres decreased.

Adult